MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Compelling Results for DA-1241 in Phase 2a MASH Trial On December 18, 2024, MetaVia Inc. (NASDAQ:MTVA) announced positive topline results from ...

Ildong Pharmaceutical stated on the 19th that it will supplement the clinical trial data for the oral antiviral drug ...

(RTTNews) - MetaVia Inc. (MTVA), Wednesday announced positive 16-week results from the two-part Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated ...

DA-1241 Demonstrated Direct Hepatic Action in Addition to Its Glucose Lowering EffectPatients Treated with DA-1241 100mg Achieved Statistically Significant Reduction in ALT Levels at Weeks 4 and 8, ...

Report by Parlance: 87% of healthcare leaders interested in AI have yet to implement it. The majority express a strong desire ...

We are republishing the latest research report under the MTVA ticker. Topline Results from Phase 2a Trial of DA-1241 in MASH Expected in December 2024 MetaVia Inc. is developing DA-1241 as a ...

MetaVia Inc. is developing DA-1241 as a treatment for metabolic dysfunction-associated steatohepatitis (MASH; formerly NASH). DA-1241 is a novel chemical entity that selectively activates GPR119 ...

The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel ...

It is also developing DA-1241, a G-protein-coupled receptor 119 (GPR119) agonist for treating MASH. MetaVia remains well-capitalized following a successful June financing, which raised up to $70 ...

It is also developing DA-1241, a G-protein-coupled receptor 119 (GPR119) agonist for treating MASH. MetaVia remains well-capitalized following a successful June financing, which raised up to $70 ...

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) is developing DA-1241 as a treatment for metabolic dysfunction-associated steatohepatitis (MASH; formerly NASH). DA-1241 is a novel chemical entity that ...

The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel ...